Godman B - Search Results

1

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Adamski J, Godman B, Ofierska-Sujkowska G, Osińska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Gustafsson R, Garuolienè K, Haycox A, Garattini S, Gustafsson LL. Adamski J, et al. Among authors: godman b. BMC Health Serv Res. 2010 Jun 7;10:153. doi: 10.1186/1472-6963-10-153. BMC Health Serv Res. 2010. PMID: 20529296 Free PMC article. Review.

2

Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.

Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Godman B, et al. Pharmacoeconomics. 2008;26(2):91-8. doi: 10.2165/00019053-200826020-00001. Pharmacoeconomics. 2008. PMID: 18198930 Review.

3

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V. Wettermark B, et al. Among authors: godman b. Pharmacoeconomics. 2008;26(7):537-50. doi: 10.2165/00019053-200826070-00001. Pharmacoeconomics. 2008. PMID: 18563945 Review.

4

Enhancing the rational use of new medicines across European health care systems.

Garattini S, Bertele' V, Godman B, Haycox A, Wettermark B, Gustafsson LL; Piperska Group. Garattini S, et al. Among authors: godman b. Eur J Clin Pharmacol. 2008 Dec;64(12):1137-8. doi: 10.1007/s00228-008-0537-z. Eur J Clin Pharmacol. 2008. PMID: 18688606 No abstract available.

5

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.

Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Godman B, et al. Expert Rev Pharmacoecon Outcomes Res. 2009 Feb;9(1):65-83. doi: 10.1586/14737167.9.1.65. Expert Rev Pharmacoecon Outcomes Res. 2009. PMID: 19371180 Review.

6

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction.

Coma A, Zara C, Godman B, Agustí A, Diogène E, Wettermark B, Haycox A. Coma A, et al. Among authors: godman b. Expert Rev Pharmacoecon Outcomes Res. 2009 Dec;9(6):569-81. doi: 10.1586/erp.09.58. Expert Rev Pharmacoecon Outcomes Res. 2009. PMID: 19941434 Review.

7

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.

Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Sermet C, et al. Among authors: godman b. Appl Health Econ Health Policy. 2010;8(1):7-24. doi: 10.1007/BF03256162. Appl Health Econ Health Policy. 2010. PMID: 20038190 Review.

8

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.

McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. McGinn D, et al. Among authors: godman b. Expert Rev Pharmacoecon Outcomes Res. 2010 Feb;10(1):73-85. doi: 10.1586/erp.09.73. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 20121565

9

Forecasting drug utilization and expenditure in a metropolitan health region.

Wettermark B, Persson ME, Wilking N, Kalin M, Korkmaz S, Hjemdahl P, Godman B, Petzold M, Gustafsson LL; Regional Drug Expert Consortium in Stockholm County Council. Wettermark B, et al. Among authors: godman b. BMC Health Serv Res. 2010 May 17;10:128. doi: 10.1186/1472-6963-10-128. BMC Health Serv Res. 2010. PMID: 20478043 Free PMC article.

10

Generic olanzapine: health authority opportunity or nightmare?

Araszkiewicz AA, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A. Araszkiewicz AA, et al. Among authors: godman b. Expert Rev Pharmacoecon Outcomes Res. 2008 Dec;8(6):549-55. doi: 10.1586/14737167.8.6.549. Expert Rev Pharmacoecon Outcomes Res. 2008. PMID: 20528365

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

481 results

Search Page